

# HOUSE BILL 1414

J1

8lr3387

---

By: **Delegates A. Washington and Healey**  
Introduced and read first time: February 9, 2018  
Assigned to: Health and Government Operations

---

## A BILL ENTITLED

1 AN ACT concerning

2 **Sickle–Cell Trait Screening, Treatment, Education, and Public Awareness**  
3 **(Journey’s Law)**

4 FOR the purpose of requiring the Statewide Steering Committee on Services for Adults  
5 with Sickle–Cell Disease, to work in conjunction with members of the medical  
6 community in leading a certain comprehensive education and treatment program for  
7 which the Steering Committee is required to seek grant funding; calling on the  
8 Maryland Department of Health, in conjunction with local health departments and  
9 the Steering Committee, to develop a certain public awareness campaign; and  
10 generally relating to screening, treatment, education, and public awareness for  
11 individuals with the sickle–cell trait.

12 BY repealing and reenacting, with amendments,  
13 Article – Health – General  
14 Section 18–506  
15 Annotated Code of Maryland  
16 (2015 Replacement Volume and 2017 Supplement)

17 Preamble

18 WHEREAS, Sickle–cell disease is the most common inherited blood disorder in the  
19 United States, affecting approximately 100,000 Americans; and

20 WHEREAS, More than 3,000,000 people in the United States have the sickle–cell  
21 trait, and many who do are unaware of their status; and

22 WHEREAS, In 2010, the total number of babies born with the sickle–cell trait was  
23 estimated to have exceeded 60,000, and the total United States incidence estimate was 15.5  
24 cases per 1,000 births; and

25 WHEREAS, African Americans, with a rate of 1 in 12 carrying the sickle–cell trait,

---

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



1 and Hispanic Americans, with a rate of 1 in 100 carrying the sickle-cell trait, are most at  
2 risk for carrying the sickle-cell trait; and

3 WHEREAS, The trait has been found in individuals of African, Asian, European, and  
4 Middle Eastern origin; and

5 WHEREAS, Individuals who have the sickle-cell trait have a 1-in-2 chance of  
6 passing on the abnormal sickle-cell gene to future offspring and, if their spouses also have  
7 the trait, a 1-in-4 chance of having children with sickle-cell disease; and

8 WHEREAS, Individuals with the sickle-cell trait have the same life expectancy as  
9 the general population, but are at risk for certain conditions, including blood in the urine,  
10 kidney cancer, complications with trauma to the eye, spleen tissue death at high altitudes,  
11 and false positives on A1C type 2 diabetes tests; and

12 WHEREAS, According to a 2007 study in the American Journal of Medical Genetics,  
13 despite a universal requirement of screening for the sickle-cell trait in every state, most  
14 states lack a protocol for disseminating the results, and parents are notified only 37% of  
15 the time; and

16 WHEREAS, The limited research regarding the communication of sickle-cell trait  
17 test results to parents demonstrates that there is a high prevalence of misleading  
18 information being communicated to new parents; and

19 WHEREAS, No studies have examined whether information on sickle-cell trait test  
20 results is being accurately communicated to an individual, whether by a family member or  
21 health care provider, prior to the individual becoming a parent;

22 WHEREAS, The General Assembly recognizes the importance of ensuring that  
23 Marylanders can make informed health decisions when they are aware of their sickle-cell  
24 trait status;

25 WHEREAS, The General Assembly recognizes the ongoing challenges in addressing  
26 health outcomes among people with the sickle-cell trait and sickle-cell disease; and

27 WHEREAS, The General Assembly commits to ensuring support for research that  
28 expands our understanding of sickle-cell trait, its implications, and the associated health  
29 risks; now, therefore, be it

30 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,  
31 That the Laws of Maryland read as follows:

32 **Article – Health – General**

33 18–506.

34 (a) In this section, “Steering Committee” means the Statewide Steering

1 Committee on Services for Adults with Sickle Cell Disease.

2 (b) There is a Statewide Steering Committee on Services for Adults with Sickle  
3 Cell Disease.

4 (c) The Steering Committee shall include representatives from:

5 (1) Local and national groups that advocate for individuals with sickle cell  
6 disease;

7 (2) Interest and support groups for individuals with sickle cell disease;

8 (3) The Genetic Alliance;

9 (4) Faith-based organizations;

10 (5) Community and consumer groups;

11 (6) Academic and private clinical settings with knowledge and experience  
12 caring for adults with sickle cell disease;

13 (7) Area hospitals caring for individuals with sickle cell disease; and

14 (8) Pediatric clinics that care for children with sickle cell disease.

15 (d) The Steering Committee shall:

16 (1) Establish institution and community partnerships;

17 (2) Establish a statewide network of stakeholders who care for individuals  
18 with sickle cell disease;

19 (3) Educate individuals with sickle cell disease, the public, and health care  
20 providers about the State options for care of sickle cell disease; and

21 (4) Seek grant funding to:

22 (i) Develop and establish a case management system for adults with  
23 sickle cell disease;

24 (ii) Establish an adult sickle cell disease day infusion center;

25 (iii) Develop, implement, and, **WORKING IN CONJUNCTION WITH**  
26 **MEMBERS OF THE MEDICAL COMMUNITY**, lead a State comprehensive education and  
27 treatment program for adults with sickle cell disease; and

28 (iv) Develop and implement a health care provider awareness and

1 education campaign to increase provider awareness of health disparities, community  
2 dynamics, cultural practice, behavioral and psychosocial issues, and the use of  
3 standardized treatment and emergency room protocols.

4 **(E) THE DEPARTMENT, IN COLLABORATION WITH THE STEERING**  
5 **COMMITTEE AND LOCAL HEALTH PLANNING AGENCIES, SHALL DEVELOP A PUBLIC**  
6 **AWARENESS CAMPAIGN ON THE IMPORTANCE OF:**

7 **(1) AN INDIVIDUAL KNOWING THE INDIVIDUAL'S SICKLE CELL TRAIT**  
8 **STATUS;**

9 **(2) AN INDIVIDUAL RECEIVING SCREENING FOR THE SICKLE CELL**  
10 **TRAIT; AND**

11 **(3) AN INDIVIDUAL WHO CARRIES THE SICKLE CELL TRAIT**  
12 **RECEIVING COUNSELING.**

13 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect  
14 October 1, 2018.